The use of immunomodulating therapy as part of complex treatment of secondary peritonitis induces reduction of inflammation in patients of different age

We present experience of using anti-thymocytic immunoglobulin (ATG) in complex therapy of patients with extensive secondary peritonitis at the age of 29-83 years. The research was based on 60 patient cases: 29 (48%) of whom were given anti-thymocytic immunoglobulin (ATG) Antilymfolin in post operati...

Full description

Saved in:
Bibliographic Details
Published inAdvances in gerontology = Uspekhi gerontologii Vol. 24; no. 3; p. 488
Main Authors Epifanova, N Iu, Koniaev, I G, Epifanov, Iu A, Golubeva, V L, Serova, L D
Format Journal Article
LanguageRussian
Published Russia (Federation) 2011
Subjects
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Antilymphocyte Serum - administration & dosage
Antilymphocyte Serum - immunology
Combined Modality Therapy
Digestive System
Humans
Immune System - drug effects
Immunologic Factors - administration & dosage
Immunologic Factors - immunology
Immunomodulation
Inflammation - immunology
Inflammation - therapy
Middle Aged
Monitoring, Immunologic
Peritonitis - etiology
Peritonitis - immunology
Peritonitis - therapy
Postoperative Complications
Rupture, Spontaneous - complications
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:We present experience of using anti-thymocytic immunoglobulin (ATG) in complex therapy of patients with extensive secondary peritonitis at the age of 29-83 years. The research was based on 60 patient cases: 29 (48%) of whom were given anti-thymocytic immunoglobulin (ATG) Antilymfolin in post operative period and 31 patient of the control group who did not receive immunomodulating therapy within the complex treatment. The received data clearly demonstrates the effectiveness of anti-thymocytic immunoglobulin (ATG) usage for normalization of innate immunity indices and inflammation reduction. Immunostimulating effect in patients given anti-thymocytic immunoglobulin (ATG) could be seen on the fourth day of the threatment. The drug is equally effective in patients of young and middle age as well as in patients of elderly and senility age. The positive influence of anti-thymocytic immunoglobulin (ATG) on inflammation is shown with the reduction of CRP, gamma-globuline, alpha1-protein fraction serum levels normalization. The use of Antilymfolin induces the regression of inflammation and apparently improves the quality and duration of treatment and rehabilitation.
ISSN:1561-9125